Supriya Lifescience Ltd

Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Supriya Lifescience Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a strong day change of 6.05%, the stock’s technical indicators present a nuanced picture, with momentum oscillating between mildly bearish and mildly bullish trends across different timeframes.

Supriya Lifescience Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s MarketsMOJO grade was downgraded from Hold to Sell on 27 February 2026, reflecting deteriorating technical and price action metrics amid a 4.82% drop in the latest trading session.

Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. This downgrade, reflected in its MarketsMOJO grade moving from Hold to Sell on 27 February 2026, underscores growing caution among investors amid mixed price action and subdued relative strength compared to benchmark indices.

Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Supriya Lifescience Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest daily price increase of 1.22%, the stock’s broader technical signals suggest cautious investor sentiment amid mixed momentum cues.

Supriya Lifescience Ltd witnessed a robust start to trading on 8 April 2026, opening with a notable gap up of 9.21%, reflecting positive market sentiment in the Pharmaceuticals & Biotechnology sector. The stock outperformed its sector peers and the broader market indices, sustaining momentum through a volatile session.

Supriya Lifescience Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its technical outlook deteriorate from mildly bearish to bearish, reflecting a shift in price momentum and mixed signals from key technical indicators. Despite a modest weekly price gain, the stock’s overall trend and momentum indicators suggest caution for investors amid a challenging market environment.

Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into its performance and outlook.

The Sensex gained 2.49% on 1 Apr 2026, yet Supriya Lifescience Ltd outpaced the broader market with a 7.35% rally, reaching an intraday high of Rs 622. This 5.28-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector's 2.07% gain highlights a stock-specific momentum shift rather than a mere market tailwind.

Despite a broader market rally, Supriya Lifescience Ltd has slipped to a fresh 52-week low of Rs 545.65 on 24 Mar 2026, extending a recent downtrend that has seen the stock lose nearly 6% over two sessions. This decline contrasts sharply with the Sensex's modest gains and highlights stock-specific pressures weighing on the pharmaceutical company.

Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

A sharp decline of 4.28% today dragged Supriya Lifescience Ltd to a fresh 52-week low of Rs 558.5, extending a downward trajectory that has seen the stock underperform the broader market significantly over the past year.

Supriya Lifescience Ltd’s stock declined to a fresh 52-week low of Rs.565 today, marking a continuation of its recent downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed over the past year, reflecting a combination of valuation concerns and subdued growth metrics.

Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Supriya Lifescience Ltd’s stock declined sharply today, hitting a new 52-week low of Rs.573.45. This drop comes amid broader market weakness and follows two days of gains, marking a notable reversal in the stock’s recent trend.

Supriya Lifescience Ltd witnessed a significant intraday decline on 9 Mar 2026, touching a new 52-week low of Rs 579.9 as the stock faced pronounced selling pressure, underperforming its sector and broader market indices amid a generally weak market environment.